Unicycive Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Agreements (Details)

Significant Agreements (Details) - USD ($)									1 Months Ended		3 Months Ended			9 Months Ended			12 Months Ended
Significant Agreements (Details) - USD ($)	Apr. 10, 2023	Mar. 31, 2023	Feb. 01, 2023	Jul. 14, 2022	Feb. 09, 2022	Jan. 06, 2022	Jul. 19, 2021	Jul. 13, 2021	Sep. 30, 2018	Oct. 31, 2017	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2021	Dec. 31, 2023	Feb. 28, 2023	Aug. 31, 2022
Significant Agreements [Line Items]
Agreement due payments										$ 1,650,000
Second clinical trial payment										$ 50,000
Percentage of royalty payment										2.00%
Common stock valued
Public market capitalization								$ 50,000,000
Anti-dilution shares of common stock (in Shares)											209,993,175	176,063,976		209,993,175	176,063,976
Research and development expenses																$ 2,200,000
Sublicense income percentage																40.00%
Accounts payable or accrued expense																	$ 2,000,000
Revision overall budget						$ 2,900,000
Prepaid expenses and other current assets											$ 5,394,000			$ 5,394,000			3,698,000
Research related payments	$ 2,900,000	$ 100,000
Milestone payments			$ 3,700,000
Payment amount														3,700,000
Minimum [Member]
Significant Agreements [Line Items]
Royalties percentage				7.00%
Maximum [Member]
Significant Agreements [Line Items]
Royalties percentage				10.00%
Common Stock [Member]
Significant Agreements [Line Items]
Anti-dilution shares of common stock (in Shares)								438,374
Lotus International Pte Ltd [Member]
Significant Agreements [Line Items]
Sublicense income percentage															20.00%
Syneos Health LLC [Member]
Significant Agreements [Line Items]
Research and development expenses							$ 2,300,000
Quotient Sciences Limited [Member]
Significant Agreements [Line Items]
Research and development expenses						$ 3,700,000
Spectrum Pharmaceuticals, Inc. [Member]
Significant Agreements [Line Items]
Issued of common shares (in Shares)									313,663
Common stock valued									$ 4,000
Public market capitalization									$ 50,000,000
Sublicense income percentage																20.00%
Altair Nanomaterials, Inc [Member]
Significant Agreements [Line Items]
Required to pay																$ 200,000
Altair [Member]
Significant Agreements [Line Items]
Required to pay																$ 4,500,000
Quotient Sciences Limited [Member]
Significant Agreements [Line Items]
Related payments											2,800,000			2,800,000
Payments to related party														2,800,000
Prepaid expenses and other current assets											600,000			600,000			600,000
CBCC Global Research Inc [Member]
Significant Agreements [Line Items]
Research and development expenses					$ 1,400,000
Initial agreement amount		400,000
Research related payments		$ 400,000
Inotiv [Member]
Significant Agreements [Line Items]
Payments to related party														2,900,000
Prepaid expenses and other current assets											$ 100,000			100,000			300,000
Lee’s Pharmaceutical (HK) Limited [Member]
Significant Agreements [Line Items]
Significant payment received				$ 1,000,000
Milestone payments				$ 1,000,000
Oxylanthanum Carbonate [Member]
Significant Agreements [Line Items]
Related payments																	2,700,000
Research related payments																	$ 2,700,000
Lotus International Pte Ltd [Member]
Significant Agreements [Line Items]
Significant payment received			$ 700,000
Shilpa Medicare Ltd [Member]
Significant Agreements [Line Items]
Payment amount														$ 3,000,000
Exclusive license agreement [Member]
Significant Agreements [Line Items]
Agreement due payments										$ 50,000
Sublicense Development Agreement [Member]
Significant Agreements [Line Items]
Significant payment received																		$ 700,000	$ 1,000,000
Investment [Member] \| Spectrum Pharmaceuticals, Inc. [Member]
Significant Agreements [Line Items]
Interest on ownership									4.00%